Eduard Valenzuela, MD, FAAP
Pediatric Solutions, LLC, Houston, Texas
ORCID: 0009-0004-6269-5116
Document Type: Mechanism of Action and Evidence Review
Published: 2026-09-18
DOI: https://doi.org/10.5281/zenodo.22820922
PDF Version: https://zenodo.org/records/22820922/files/Pyrithione-Zinc-for-Infantile-Seborrheic-Dermatitis.pdf
Abstract
Mechanistic Basis and Evidence Scope
Pyrithione zinc (zinc pyrithione, ZnPT) is an established topical active ingredient for dandruff and seborrheic dermatitis, with molecular evidence demonstrating antifungal activity against Malassezia species and randomized clinical evidence of efficacy in adult scalp disease. These findings provide a mechanistic rationale for investigation in infantile seborrheic dermatitis (ISD), commonly known as cradle cap when involving the scalp, although the contribution of Malassezia to ISD pathogenesis remains incompletely defined. Direct infant-specific randomized efficacy and pharmacokinetic data for zinc pyrithione remain limited.
The 2019 Cochrane systematic review of ISD interventions identified only six randomized trials, rated the certainty of evidence for all studied comparisons as very low, and identified no eligible trials of commonly used antifungal treatments. Accordingly, the review demonstrates the broader weakness of the infant treatment evidence base but does not directly evaluate zinc pyrithione (Victoire et al., 2019).
Outside the infant population, human exposure studies and probabilistic modeling indicate very low systemic exposure to zinc pyrithione under studied rinse-off conditions. An aggregate exposure model estimated internal exposure of 0.01-1.29 micrograms/kg/day among 95th-percentile users, while more intensive experimental human exposure involving daily 2% zinc pyrithione shampoo together with a leave-on zinc pyrithione tonic also produced systemic exposure in the low micrograms/kg/day range (Tozer et al., 2015; Mangion et al., 2021).
These data do not establish infant-specific pharmacokinetics or safety. This narrative review integrates mechanistic, adult clinical, topical exposure, toxicologic, regulatory, and pediatric evidence while explicitly distinguishing direct evidence from extrapolation. The available evidence supports a biologically plausible and experimentally supported rationale for infant-specific clinical investigation, but dedicated studies remain necessary to establish efficacy, pharmacokinetics, and safety in infants.
Keywords: infantile seborrheic dermatitis; cradle cap; zinc pyrithione; pyrithione zinc; Malassezia; pediatric dermatology; medicated shampoo
1. Introduction
1.1 Presentation and Prevalence of Infantile Seborrheic Dermatitis
Infantile seborrheic dermatitis is a common, generally benign and self-limited inflammatory skin disorder characterized by erythema with greasy or adherent scale. When localized to the scalp, it is commonly referred to as cradle cap. The condition may also involve the eyebrows and face, postauricular regions, neck folds, axillae, groin, and other intertriginous sites.
ISD has a marked age-dependent prevalence. In an Australian population-based study, seborrheic dermatitis was identified in 71.7% of infants younger than three months and 44.5% of children younger than one year, with prevalence decreasing substantially thereafter; most cases were minimal or mild (Foley et al., 2003). The majority of cases improve spontaneously during infancy and resolve within the first year of life (Poindexter et al., 2009; Victoire et al., 2019).
1.2 Classification, Scope, and Literature Identification
This paper is a mechanism-of-action and narrative evidence review. It addresses the biological rationale, clinical efficacy evidence, topical pharmacokinetic and exposure evidence, toxicologic and regulatory context, and pediatric evidence gaps relevant to zinc pyrithione as a potential topical treatment for ISD. It does not evaluate any single commercial formulation.
Literature searches were conducted on September 4, 2026, using PubMed/MEDLINE and the Cochrane Library, supplemented by official U.S. Food and Drug Administration and European regulatory sources and backward citation review of relevant primary studies and reviews. Search concepts included combinations of "zinc pyrithione," "pyrithione zinc," "infantile seborrheic dermatitis," "infantile seborrhoeic dermatitis," "cradle cap," "Malassezia," "dandruff," "seborrheic dermatitis," "oleic acid," "lipase," "absorption," "percutaneous absorption," "pharmacokinetics," "systemic exposure," "reproductive toxicity," and "developmental toxicity."
Evidence was interpreted according to both population and evidence type. Infant clinical evidence was distinguished from adult clinical evidence; mechanistic and microbiological evidence from clinical outcome evidence; topical exposure and pharmacokinetic studies from toxicology studies; and regulatory hazard classifications from exposure-based risk assessments. Where a secondary source made an ingredient-specific claim, the underlying citation was reviewed when available to determine whether the cited evidence directly supported the ingredient, population, route of exposure, and outcome being discussed.
This was not a systematic review. No prospective protocol, PRISMA methodology, formal meta-analysis, or independent risk-of-bias assessment was performed. Statements concerning absence of evidence therefore refer to evidence identified through this narrative review and should not be interpreted as proof that no additional published or unpublished evidence exists.
2. Background: Pathophysiology and Current Management of ISD
2.1 Etiology and Anatomical Distribution
The etiology of infantile seborrheic dermatitis remains incompletely understood and is likely multifactorial. Proposed contributors include sebaceous activity, epidermal barrier function, host inflammatory responses, lipid composition, and interactions with the cutaneous microbiome, including Malassezia species. Contemporary reviews emphasize both similarities and potentially important differences between infantile and adult seborrheic dermatitis (Borda & Wikramanayake, 2015; Rau et al., 2024).
In adult dandruff and seborrheic dermatitis, Malassezia lipases hydrolyze sebaceous triglycerides and generate free fatty acids, including oleic acid, that can provoke barrier disturbance and desquamation in susceptible individuals. Experimental application of oleic acid has produced dandruff-like flaking in susceptible subjects but not in unaffected controls, supporting an important role for host susceptibility in this pathway (DeAngelis et al., 2005; Dawson, 2007; Borda & Wikramanayake, 2015).
This mechanism is well supported in adult dandruff biology but should not be assumed to explain infant disease identically. Current reviews of ISD continue to identify sebaceous activity, lipid abnormalities, epidermal-barrier function, microbiome composition, and immune responsiveness as candidate contributors, while emphasizing that the relative importance of these factors remains uncertain (Rau et al., 2024).
Clinically, the distribution of ISD is consistent with involvement of sebaceous and intertriginous regions. Scalp disease is termed cradle cap, but erythema and scale may also occur around the eyebrows, ears, face, neck folds, axillae, groin, and other folds.
2.2 Current Topical Management and Antiseborrheic Shampoos
Topical measures constitute the mainstay of management for pediatric seborrheic dermatitis. Depending on severity, distribution, and persistence, management may include gentle cleansing, scale softening and mechanical removal, antifungal therapy, and short courses of low-potency topical corticosteroids for inflammatory disease (Poindexter et al., 2009; Cheong et al., 2016; Chiriac & Wollina, 2024).
Pediatric-specific clinical reviews describe shampoos containing zinc pyrithione or selenium disulfide among topical treatment options for scalp seborrheic dermatitis and dandruff (Chiriac & Wollina, 2024). This is evidence of recognized clinical use rather than evidence from dedicated randomized infant zinc-pyrithione trials. The distinction is important: inclusion in clinical guidance establishes treatment context but does not establish infant-specific efficacy or safety.
2.3 Regulatory Context
In the United States, pyrithione zinc is included in FDA OTC Monograph M032 as an active ingredient for the control of seborrheic dermatitis at concentrations of 0.95% to 2% when formulated for brief-exposure rinse-off use and 0.1% to 0.25% when formulated as a leave-on product (U.S. Food and Drug Administration, 2021). This regulatory status establishes the conditions under which an appropriately formulated and labeled OTC product may be marketed for seborrheic dermatitis; it does not constitute infant-specific trial evidence or establish a separate cradle-cap indication.
European regulatory treatment of zinc pyrithione illustrates the distinction between intrinsic hazard classification and exposure-based risk assessment. Zinc pyrithione was harmonized under the EU Classification, Labelling and Packaging framework as reproductive toxicant Category 1B for developmental toxicity (H360D), based principally on developmental effects observed in experimental-animal studies following systemic exposure. This hazard classification does not itself establish risk from a particular topical use. The Scientific Committee on Consumer Safety (SCCS) separately evaluated consumer exposure and concluded that zinc pyrithione was safe as an anti-dandruff ingredient in rinse-off hair products at concentrations up to 1% under the conditions assessed (SCCS, 2020).
Under EU cosmetics law, however, a Category 1A or 1B CMR substance could remain in cosmetics only by exception, and all statutory criteria for that exception had to be satisfied. Although the SCCS safety criterion was met, it had not been established that no suitable alternative anti-dandruff ingredients were available. Zinc pyrithione was therefore added to the EU list of substances prohibited in cosmetic products. The prohibition consequently should not be interpreted as an SCCS determination that the evaluated 1% rinse-off exposure was unsafe (SCCS, 2020; European Commission, 2021).
3. Mechanism of Action of Zinc Pyrithione
3.1 Cellular and Molecular Mechanism
Zinc pyrithione exerts antifungal activity against Malassezia in part through disruption of intracellular metal homeostasis and iron-sulfur-dependent metabolism. Malassezia globosa and M. restricta are among the predominant Malassezia species associated with dandruff and seborrheic dermatitis, although their relative abundance and biological significance vary by population, body site, and study methodology (Dawson, 2007).
Reeder et al. (2011) demonstrated that zinc pyrithione increased intracellular copper and impaired iron-sulfur-cluster-containing proteins in Saccharomyces cerevisiae. Importantly, they also demonstrated zinc-pyrithione-mediated copper accumulation and growth inhibition in M. globosa, supporting a copper-dependent mechanism in that species.
Park et al. (2018), studying M. restricta directly, observed a different metal-response pattern. Zinc pyrithione produced a marked dose-dependent increase in intracellular zinc together with evidence of disruption of iron-sulfur cluster biosynthesis and mitochondrial function. Transcriptomic analysis also demonstrated downregulation of multiple lipase genes, including lipases implicated in the organism's interaction with the lipid-rich scalp environment (Park et al., 2018).
Taken together, these findings favor a multifactorial and potentially species-dependent mechanism involving altered metal homeostasis, disruption of iron-sulfur-dependent metabolism, mitochondrial dysfunction, and effects on lipid-utilization pathways rather than a single universal intracellular mechanism operating identically across all Malassezia species.
3.2 Targeted Delivery to the Scalp Surface and Follicular Infundibulum
The effectiveness of a rinse-off topical antifungal depends not only on intrinsic antifungal activity but also on deposition and persistence at relevant skin sites. Zinc pyrithione has low aqueous solubility, favoring deposition of particulate active material on the skin after rinsing. Malassezia inhabits both the interfollicular scalp surface and follicular microenvironments, particularly the upper follicular infundibulum.
Delivery studies summarized by Mangion et al. demonstrate deposition of zinc pyrithione on the scalp and within follicular structures, providing a plausible mechanism for sustained local antifungal activity after rinse-off application (Mangion et al., 2021).
Localized deposition, however, should not be equated with zero systemic absorption. Dermal exposure has been quantitatively studied and is considered separately below.
3.3 Clinical Corroboration in Adult Populations
Human studies corroborate the antifungal activity and clinical relevance of zinc pyrithione, although they do not directly establish that the complete intracellular mechanisms observed experimentally occur identically in vivo.
Leong et al. (2021) demonstrated low inhibitory concentrations of zinc pyrithione against Malassezia in vitro and documented a measurable reduction in scalp M. restricta following zinc-pyrithione shampoo treatment in a longitudinal human study. This provides direct evidence that topical zinc pyrithione can reduce Malassezia burden on human scalp (Leong et al., 2021).
Randomized clinical evidence also supports clinically meaningful activity in adult dandruff and seborrheic dermatitis. Piérard-Franchimont et al. (2002) compared 1% zinc pyrithione shampoo with 2% ketoconazole shampoo in 331 eligible subjects with severe dandruff or seborrheic dermatitis. Both treatments produced substantial improvement after four weeks: total dandruff severity improved by approximately 67% with zinc pyrithione and 73% with ketoconazole. Ketoconazole was statistically superior and was associated with lower recurrence during untreated follow-up (Piérard-Franchimont et al., 2002).
These findings are relevant because they demonstrate clinical efficacy of zinc pyrithione without requiring the conclusion that it is the most effective antifungal treatment. Schwartz et al. (2013) further demonstrated clinical efficacy of zinc-pyrithione-based anti-dandruff formulations in randomized adult clinical testing (Schwartz et al., 2013).
Together, these data support translation from molecular antifungal activity to reduction of scalp Malassezia and clinical benefit in adult scalp disease. They do not establish efficacy in infants.
4. The Infant Clinical Trial and Exposure Evidence Base
4.1 Systematic Review Evidence and the Scope of the Infant Evidence Gap
The 2019 Cochrane systematic review by Victoire et al. provides a systematic assessment of the ISD intervention literature. The review used standard Cochrane methodology; its principal limitation was not the systematic-review process but the small and methodologically weak primary evidence available for inclusion.
The review identified six randomized controlled trials involving 310 randomized children, with 297 included in analysis. Trials were short, ranging from 10 to 42 days, and evaluated heterogeneous interventions. The certainty of evidence was rated very low for every comparison because of risk of bias, imprecision, indirectness, heterogeneous outcome measures, and poor trial reporting (Victoire et al., 2019).
Crucially for the present review, no eligible trials evaluated commonly used antifungal treatments. Cochrane specifically identified antifungals, shampoos and brushing, emollients, corticosteroids, and other commonly recommended interventions as priorities for adequately powered controlled study (Victoire et al., 2019).
A targeted PubMed search performed for this review combining zinc-pyrithione terms with infantile seborrheic dermatitis and cradle cap returned no records. Because a zero-result targeted query does not prove that no relevant study exists, this finding is interpreted together with the Cochrane review and broader pediatric literature rather than as a standalone conclusion.
Accordingly, the Cochrane review establishes the breadth and weakness of the infant treatment evidence base but does not directly test zinc pyrithione. Its findings should not be interpreted as evidence either demonstrating or refuting the infant-specific efficacy or safety of zinc pyrithione.
4.2 Ingredient-Specific Systemic Exposure and Safety Evidence
Some secondary clinical literature applies generalized caution to several antiseborrheic or keratolytic shampoo ingredients in newborns. Micali et al. (2021), for example, group salicylic acid, sulfur, selenium, and zinc pyrithione together and state that these shampoos are generally not recommended because of the possibility of systemic absorption (Micali et al., 2021).
Examination of the cited evidence illustrates the importance of ingredient-level precision. Micali et al. cite the consensus guidance of Cheong et al. (2016). In the infant treatment section of that source, the explicit evidence concerning absence of systemic absorption pertains to ketoconazole shampoo, based on a small study of 13 infants; Cheong et al. do not provide analogous zinc-pyrithione-specific infant pharmacokinetic data (Cheong et al., 2016; Brodell et al., 1998).
This does not establish that generalized caution regarding zinc pyrithione is incorrect. It establishes a narrower point: the cited source does not itself demonstrate clinically meaningful systemic absorption of zinc pyrithione in infants.
Available human exposure studies and probabilistic modeling indicate very low systemic exposure to zinc pyrithione under studied rinse-off use conditions. In a probabilistic aggregate-exposure model incorporating amount of product used, frequency of use, co-use of multiple rinse-off products, and market share, estimated internal exposure among 95th-percentile users ranged from 0.01 to 1.29 micrograms/kg/day (Tozer et al., 2015).
Mangion et al. (2021) summarize a deliberately intensive human exposure regimen involving daily use of 2% zinc pyrithione shampoo plus a 0.25% leave-on zinc-pyrithione tonic for four days, in which the highest reported systemic exposure was 4.38 micrograms/kg/day. These values are adult exposure data and should not be interpreted as infant pharmacokinetics.
For toxicologic context, 0.5 mg/kg/day - equivalent to 500 micrograms/kg/day - was used as a toxicologic point of departure in SCCS risk assessment (SCCS, 2018). The upper end of the modeled 95th-percentile consumer exposure, 1.29 micrograms/kg/day, is approximately 388-fold lower than that value; the intensive 4.38 micrograms/kg/day exposure described by Mangion is more than 100-fold lower. These numerical comparisons provide context only and should not be interpreted as formal infant-specific margins of safety.
The SCCS human-exposure assessment independently supports low dermal uptake. For risk assessment, SCCS used a conservative dermal-absorption assumption of 1%. The supporting human study found that up to 0.22% of applied zinc pyrithione was recovered in urine after combined shampoo and leave-on exposure; accounting for unmeasured later excretion and possible tissue retention, SCCS concluded that total absorption was most probably not greater than 1% (SCCS, 2020).
The SCCS also noted that prior topical reproductive studies did not demonstrate reproductive effects at the highest dermal doses tested and concluded that zinc pyrithione was unlikely to be of concern with respect to fertility, while acknowledging developmental effects in newer systemic animal studies (SCCS, 2020). These toxicologic observations provide useful route-of-exposure context but do not substitute for dedicated infant safety studies.
Taken together, the exposure literature supports a more precise conclusion than either "zinc pyrithione is not absorbed" or "systemic absorption in infants is established." Quantitative studies demonstrate limited systemic exposure under studied adult and experimental conditions. What remains uncharacterized is whether infant skin characteristics, body-surface-area-to-mass ratio, barrier integrity, treated surface area, formulation, and use pattern materially alter that exposure profile after clinically relevant brief-exposure rinse-off application.
4.3 Net Assessment
Dedicated infant-specific randomized efficacy trials and pharmacokinetic studies of zinc pyrithione remain insufficient.
The available literature therefore neither establishes clinically meaningful systemic exposure to zinc pyrithione in infants nor rules such exposure out. This represents a population-specific evidence gap rather than evidence in itself of a zinc-pyrithione-specific systemic hazard.
This distinction is particularly important when zinc pyrithione is discussed alongside compounds with different absorption and toxicity profiles. Salicylic acid, for example, has documented systemic salicylate toxicity following excessive topical exposure in infants (Oualha et al., 2012). Evidence specific to one antiseborrheic ingredient should not automatically be transferred to another merely because both are used for scaling disorders.
Adult and ex vivo zinc-pyrithione data demonstrating very low but measurable dermal exposure (Rush et al., 2019) are relevant to biological plausibility, risk assessment, and future study design. They cannot establish infant-specific efficacy or safety.
5. Discussion
5.1 Efficacy Claims Rest on Mechanism and Adult-Population Data
The clinical rationale for investigating zinc pyrithione in ISD is supported by mechanistic evidence against Malassezia, targeted scalp-delivery data, reduction of Malassezia burden in human scalp studies, and randomized adult clinical efficacy data.
Direct infant-specific randomized efficacy evidence remains inadequate. The absence of dedicated infant zinc-pyrithione trials is therefore an ingredient-specific limitation, but it occurs within a broader ISD treatment literature in which many commonly recommended interventions have also not been adequately evaluated in randomized controlled trials.
The appropriate inference is not that adult data establish infant efficacy. Rather, the adult and mechanistic evidence provide a rational basis for conducting direct infant studies.
5.2 Ingredient-Level Precision Matters in Safety Discussion
Safety discussions concerning topical therapy in infants should distinguish among compounds rather than treating antiseborrheic ingredients as pharmacologically interchangeable.
For zinc pyrithione, quantitative adult and ex vivo evidence demonstrates low systemic exposure under studied topical conditions. Secondary sources that group zinc pyrithione with salicylic acid, sulfur, or selenium under generalized absorption cautions should therefore not be interpreted as demonstrating equivalent pharmacokinetics or equivalent evidence of systemic toxicity for each ingredient.
At the same time, absence of identified infant zinc-pyrithione toxicity should not be converted into a positive assertion of infant safety. Population-appropriate safety evidence is required to characterize risk definitively.
5.3 The Role of Mechanism and Evidence Reviews Given Limited Pediatric Trial Data
When high-quality pediatric randomized trials are scarce, mechanism-of-action and evidence reviews serve a distinct purpose. They clarify which conclusions derive from direct pediatric evidence, which are supported by adult clinical studies, which derive from experimental biology or exposure modeling, and which remain extrapolations.
This hierarchy is particularly important in ISD because the condition is common, generally mild, and self-limited. A favorable natural history makes uncontrolled clinical improvement particularly difficult to distinguish from treatment effect.
Mechanistic evidence does not substitute for an infant randomized controlled trial. Its value is to establish biological coherence, identify plausible therapeutic targets, inform dose and exposure questions, and help determine which interventions merit population-specific clinical study.
5.4 Limitations
This narrative review is limited primarily by the scarcity of direct infant-specific evidence evaluating zinc pyrithione.
Much of the mechanistic evidence derives from in vitro or experimental models, and much of the clinical evidence derives from adult scalp disease. The relationship between Malassezia and ISD remains incompletely defined, and infantile and adult seborrheic dermatitis should not be assumed to have identical pathogenesis.
The available pharmacokinetic and exposure evidence demonstrates very low systemic exposure under studied non-infant conditions, but differences in infant skin anatomy, body-surface-area-to-mass ratio, barrier integrity, formulation, disease severity, treated surface area, and frequency of application limit direct extrapolation.
This review did not employ a systematic-review protocol, prospective registration, formal PRISMA methodology, or independent risk-of-bias assessment. Absence-of-evidence statements therefore refer to evidence identified through the literature searches and citation review described above rather than proof that no other data exist.
Several important zinc-pyrithione studies have direct or indirect industry involvement. This does not invalidate their findings but is relevant when interpreting the totality of evidence. The author of the present review also has a financial interest in a company that markets a zinc-pyrithione-containing product, as disclosed below.
These limitations constrain conclusions regarding infant-specific efficacy, pharmacokinetics, and safety.
6. Research Priorities and Future Directions
6.1 Identified Priorities for Controlled Investigation
- Randomized controlled trials evaluating brief-exposure rinse-off zinc-pyrithione formulations as standalone interventions in infants with ISD using standardized and validated severity measures.
- Formal infant pharmacokinetic assessment after clinically relevant rinse-off application, including the effects of treated surface area, barrier integrity, contact time, frequency, and formulation.
- Comparative trials against commonly used approaches, including gentle cleansing and scale removal, topical azole antifungals, and appropriately selected anti-inflammatory therapies.
- Evaluation of time to improvement, complete resolution, recurrence, and any need for maintenance therapy.
- Prospective reporting of local adverse effects, systemic exposure, treatment discontinuation, and caregiver acceptability.
- Trial designs capable of distinguishing treatment-associated improvement from spontaneous resolution given the favorable natural history of ISD.
These priorities are consistent with Cochrane's broader call for better trials of commonly recommended ISD interventions, including shampoos and brushing, antifungal agents, corticosteroids, and emollient approaches (Victoire et al., 2019).
6.2 Research Gap and Need for Population-Specific Evidence
The absence of dedicated infant randomized trials and pharmacokinetic studies identifies a clear need for population-specific investigation.
Existing molecular, microbiological, delivery, exposure, and adult clinical evidence provides a substantial mechanistic rationale for such studies. What remains unresolved is whether efficacy and exposure characteristics established or inferred in non-infant settings translate to infants at concentrations, contact times, formulations, treated surface areas, and use patterns relevant to ISD.
The central research question is therefore no longer simply whether zinc pyrithione has antifungal activity against Malassezia. That is well supported. The clinically relevant questions are whether this activity produces meaningful benefit in infantile seborrheic dermatitis, what systemic exposure occurs in infants under realistic rinse-off conditions, and how the benefit-risk profile compares with alternative management approaches.
7. Conclusion
7.1 Mechanism Summary and Clinical Rationale
Zinc pyrithione has a well-supported antifungal mechanism against Malassezia species involving disruption of intracellular metal homeostasis and iron-sulfur-dependent metabolism, with additional effects on mitochondrial function and lipid-utilization pathways. Findings differ somewhat between M. globosa and M. restricta, supporting complementary and potentially species-dependent mechanisms rather than a single universal pathway (Reeder et al., 2011; Park et al., 2018).
Topical-delivery studies support deposition of zinc pyrithione at scalp and follicular sites where Malassezia resides. Human studies demonstrate reductions in Malassezia burden following zinc-pyrithione shampoo use, and randomized adult clinical studies demonstrate therapeutic benefit in dandruff and seborrheic dermatitis.
Extension of these findings to ISD is biologically plausible but remains inferential. The precise role of Malassezia in infantile disease remains incompletely defined, and dedicated infant efficacy trials are lacking.
Adult human exposure studies, human-skin experiments, probabilistic modeling, and regulatory risk assessments consistently indicate low systemic exposure under studied topical conditions. These data materially inform the risk question but cannot characterize infant pharmacokinetics directly.
The available evidence therefore supports a conclusion of infant-specific uncertainty, rather than either established infant safety or demonstrated zinc-pyrithione-specific systemic toxicity.
7.2 Next Steps for Clinical Evaluation
The 2019 Cochrane review demonstrates that the broader evidence base for ISD treatment is small and of very low certainty and, importantly, did not identify randomized trials of commonly used antifungal therapies. This finding is best understood as evidence of an unresolved treatment-evidence gap rather than evidence against zinc pyrithione specifically.
Molecular and adult clinical evidence provide a rational basis for direct investigation of zinc pyrithione in ISD, but they cannot close the pediatric evidence gap by extrapolation alone. Properly designed infant-specific randomized trials accompanied by pharmacokinetic and safety assessment under clinically relevant brief-exposure rinse-off conditions remain the necessary next step.
8. Conflict of Interest Statement
Eduard Valenzuela, MD, FAAP, is affiliated with Pediatric Solutions, LLC, which markets products containing pyrithione zinc. The author has a financial interest in Pediatric Solutions, LLC.
This review evaluates published evidence concerning pyrithione zinc and does not evaluate the efficacy or safety of any specific commercial formulation. The author's financial relationship should be considered when interpreting this narrative review.
References
Borda LJ, Wikramanayake TC. Seborrheic dermatitis and dandruff: a comprehensive review. Journal of Clinical and Investigative Dermatology. 2015;3(2). https://doi.org/10.13188/2373-1044.1000019
Brodell RT, Patel S, Venglarcik JS, Moses D, Gemmel D. The safety of ketoconazole shampoo for infantile seborrheic dermatitis. Pediatric Dermatology. 1998;15(5):406-407. https://doi.org/10.1111/j.1525-1470.1998.tb01378.x
Cheong WK, Yeung CK, Torsekar RG, et al. Treatment of seborrhoeic dermatitis in Asia: a consensus guide. Skin Appendage Disorders. 2016;1(4):187-196. https://doi.org/10.1159/000444682
Chiriac A, Wollina U. Pediatric dermatitis seborrhoica - a clinical and therapeutic review. Indian Dermatology Online Journal. 2024;15(3):383-391. https://doi.org/10.4103/idoj.idoj_593_23
Dawson TL Jr. Malassezia globosa and restricta: breakthrough understanding of the etiology and treatment of dandruff and seborrheic dermatitis through whole-genome analysis. Journal of Investigative Dermatology Symposium Proceedings. 2007;12(2):15-19. https://doi.org/10.1038/sj.jidsymp.5650049
DeAngelis YM, Gemmer CM, Kaczvinsky JR, Kenneally DC, Schwartz JR, Dawson TL Jr. Three etiologic facets of dandruff and seborrheic dermatitis: Malassezia fungi, sebaceous lipids, and individual sensitivity. Journal of Investigative Dermatology Symposium Proceedings. 2005;10(3):295-297. https://doi.org/10.1111/j.1087-0024.2005.10119.x
European Commission. Commission Regulation (EU) 2021/1902 of 29 October 2021 amending Annexes II, III and V to Regulation (EC) No 1223/2009 as regards substances classified as carcinogenic, mutagenic or toxic for reproduction. Official Journal of the European Union. 2021.
Foley P, Zuo Y, Plunkett A, Merlin K, Marks R. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Archives of Dermatology. 2003;139(3):318-322. https://doi.org/10.1001/archderm.139.3.318
Leong C, Wang J, Toi MJ, Lam YI, Goh JP, Lee SM, Dawson TL. Effect of zinc pyrithione shampoo treatment on skin commensal Malassezia. Medical Mycology. 2021;59(2):210-213. https://doi.org/10.1093/mmy/myaa068
Mangion SE, Holmes AM, Roberts MS. Targeted delivery of zinc pyrithione to skin epithelia. International Journal of Molecular Sciences. 2021;22(18):9730. https://doi.org/10.3390/ijms22189730
Micali G, Pulvirenti N, Dall'Oglio F, Tedeschi A, Quattrocchi E, Lacarrubba F. Treatment of cradle cap in infants with a new cosmetic non-steroidal gel cream: clinical, laboratory, and instrumental evaluation. Journal of Cosmetic Dermatology. 2021;20(Suppl 1):14-17. https://doi.org/10.1111/jocd.14095
Park M, Cho YJ, Lee YW, Jung WH. Understanding the mechanism of action of the anti-dandruff agent zinc pyrithione against Malassezia restricta. Scientific Reports. 2018;8:12086. https://doi.org/10.1038/s41598-018-30588-2
Piérard-Franchimont C, Goffin V, Decroix J, Piérard GE. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacology and Applied Skin Physiology. 2002;15(6):434-441. https://doi.org/10.1159/000066452
Oualha M, Dupic L, Bastian C, Bergounioux J, Bodemer C, Lesage F. Local salicylate transcutaneous absorption: an unrecognized risk of severe intoxication: a case report. Archives de Pédiatrie. 2012;19(10):1089–1092. doi:10.1016/j.arcped.2012.07.012.
Poindexter GB, Burkhart CN, Morrell DS. Therapies for pediatric seborrheic dermatitis. Pediatric Annals. 2009;38(6):333-338. https://doi.org/10.3928/00904481-20090521-01
Rau A, Silva GS, Margolis DJ, Chiesa Fuxench ZC. Adult and infantile seborrheic dermatitis: update on current state of evidence and potential research frontiers. International Journal of Dermatology. 2024;63(11):1495-1502. https://doi.org/10.1111/ijd.17324
Reeder NL, Kaplan J, Xu J, et al. Zinc pyrithione inhibits yeast growth through copper influx and inactivation of iron-sulfur proteins. Antimicrobial Agents and Chemotherapy. 2011;55(12):5753-5760. https://doi.org/10.1128/AAC.00724-11
Rush AK, Nash JF, Smith ED III, Kasting GB. Formulation and artificial sebum effects on the percutaneous absorption of zinc pyrithione through excised human skin. Skin Pharmacology and Physiology. 2019;32(4):224-234. https://doi.org/10.1159/000499477
Schwartz JR, Bacon RA, Shah R, Mizoguchi H, Tosti A. Therapeutic efficacy of anti-dandruff shampoos: a randomized clinical trial comparing products based on potentiated zinc pyrithione and zinc pyrithione/climbazole. International Journal of Cosmetic Science. 2013;35(4):381-387. https://doi.org/10.1111/ics.12055
Scientific Committee on Consumer Safety. Addendum to the Scientific Opinion on Zinc Pyrithione (P81), SCCS/1593/18. European Commission; 2018.
Scientific Committee on Consumer Safety. Opinion on Zinc Pyrithione (ZPT), Submission III, SCCS/1614/19. Final opinion adopted March 3-4, 2020. European Commission.
Tozer SA, Kelly S, O'Mahony C, Daly EJ, Nash JF. Aggregate exposure modelling of zinc pyrithione in rinse-off personal cleansing products using a person-orientated approach with market share refinement. Food and Chemical Toxicology. 2015;83:103-110. https://doi.org/10.1016/j.fct.2015.06.005
U.S. Food and Drug Administration. OTC Monograph M032: Drug Products for the Control of Dandruff, Seborrheic Dermatitis, and Psoriasis for Over-the-Counter Human Use. Final Administrative Order OTC000021; 2021.
Victoire A, Magin P, Coughlan J, van Driel ML. Interventions for infantile seborrhoeic dermatitis (including cradle cap). Cochrane Database of Systematic Reviews. 2019;(3):CD011380. https://doi.org/10.1002/14651858.CD011380.pub2
Canonical Record
This document is formally published and archived under the following DOI, which serves as the canonical record for citation custody and long-term reference.
DOI: https://doi.org/10.5281/zenodo.22820921
First published: 2026-09-18
Authorship: Eduard Valenzuela, MD, FAAP